Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroendocrine Tumors × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 76 Lung Neoplasms 36 Carcinoma, Hepatocellular 35 Small Cell Lung Carcinoma 25 Cholangiocarcinoma 18 Urinary Bladder Neoplasms 17 Breast Neoplasms 17 Neoplasms 14 Colorectal Neoplasms 13 Triple Negative Breast Neoplasms 12 Squamous Cell Carcinoma of Head and Neck 12 Biliary Tract Neoplasms 10 Liver Neoplasms 9 Pancreatic Neoplasms 8 Ovarian Neoplasms 8 Esophageal Neoplasms 8 Stomach Neoplasms 7 Recurrence 7 Neoplasm Metastasis 7 Head and Neck Neoplasms 7 Prostatic Neoplasms 6 Melanoma 6 Carcinoma, Transitional Cell 6 Carcinoma, Renal Cell 6 Bile Duct Neoplasms 6 Neoplasms by Site 5 Mesothelioma, Malignant 5 Endometrial Neoplasms 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4

Interventions

lutetium Lu 177 dotatate 15 Everolimus 10 Temozolomide 9 Nivolumab 8 Capecitabine 7 pembrolizumab 6 cabozantinib 5 Sunitinib 5 lanreotide 4 gallium Ga 68 dotatate 4 177Lu-octreotide, DOTA(0)-Tyr(3)- 4 telotristat ethyl 3 pazopanib 3 lenvatinib 3 avelumab 3 Octreotide 3 Magnetic Resonance Spectroscopy 3 Ipilimumab 3 Injections 3 Etoposide 3 Cyclophosphamide 3 Carboplatin 3 Bevacizumab 3 surufatinib 2 sintilimab 2 fosbretabulin 2 fludarabine 2 Specimen Handling 2 Positron Emission Tomography Computed Tomography 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡